Calquence, a BTK inhibitor, is now approved for first-line treatment of MCL, offering a new therapeutic option for patients ineligible for stem cell transplantation. The ECHO trial showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results